Why Shingles Deserves Your Attention (and Action)
This common viral infection can trigger chronic pain and serious complications — yet most eligible adults skip the vaccine that could prevent it.

If you've ever watched someone suffer through shingles, you know it's more than just a rash. The blistering, burning pain can be excruciating. But what many people don't realize is that shingles can leave lasting damage long after the visible symptoms fade — and there's a safe, effective vaccine that most eligible adults aren't getting.
According to reporting by WIRED, shingles is causing millions of cases of chronic pain, nerve damage, and elevated health risks each year. Yet vaccination rates remain stubbornly low, leaving countless people vulnerable to a condition that's largely preventable.
What Makes Shingles More Serious Than You Think
Shingles occurs when the varicella-zoster virus — the same one that causes chickenpox — reactivates in your body decades after your initial infection. If you've had chickenpox (and about 95% of adults have), the virus never truly leaves. It lies dormant in nerve tissue, waiting for an opportunity when your immune system weakens.
The reactivation creates a painful, blistering rash that typically wraps around one side of your torso, though it can appear anywhere on your body. For some, the acute phase is bad enough: burning pain, sensitivity to touch, and weeks of discomfort. But the real concern lies in what can happen afterward.
Post-herpetic neuralgia (PHN) affects 10-18% of shingles patients, causing nerve pain that persists for months or even years after the rash heals. This isn't ordinary discomfort — people describe it as burning, stabbing, or shooting pain that can be severe enough to interfere with sleep, daily activities, and quality of life. The risk increases significantly with age.
Beyond chronic pain, research has linked shingles to increased stroke risk in the weeks and months following an outbreak. The virus can trigger inflammation in blood vessels, potentially leading to cardiovascular complications. Eye involvement can threaten vision, and in rare cases, the infection can affect the brain or internal organs.
Why Aren't More People Getting Vaccinated?
Here's the frustrating part: we have a highly effective vaccine. The CDC recommends the shingles vaccine (Shingrix) for adults 50 and older, administered in two doses. Clinical trials show it's more than 90% effective at preventing shingles and PHN.
Yet vaccination rates tell a different story. Many eligible adults either don't know about the vaccine, underestimate their risk, or assume shingles is just an uncomfortable rash that will pass. Others face practical barriers: the vaccine can be expensive without insurance coverage, and some people experience temporary side effects like arm soreness or fatigue that deter them from completing the two-dose series.
There's also a generational knowledge gap. If you haven't witnessed someone struggle with shingles complications, it's easy to dismiss it as something that happens to other people. But with approximately one in three Americans developing shingles in their lifetime, the odds aren't in your favor.
Who's Most at Risk?
Your risk of developing shingles increases as you age, particularly after 50. That's because immune function naturally declines over time, giving the dormant virus an opportunity to reactivate. But age isn't the only factor.
People with weakened immune systems — whether from conditions like HIV, cancer treatments, or immunosuppressive medications — face higher risk at any age. Stress, both physical and emotional, can also trigger outbreaks. Even otherwise healthy adults can develop shingles during periods of significant life stress or illness.
The severity and complication risk also increase with age. While a 40-year-old might experience an uncomfortable but manageable case, a 70-year-old faces much higher odds of developing chronic pain and other serious complications.
What You Can Do
If you're 50 or older and haven't been vaccinated against shingles, it's worth having a conversation with your healthcare provider. The vaccine is recommended even if you've already had shingles, since you can get it more than once.
For those concerned about cost, it's worth checking your insurance coverage — many plans cover the vaccine, and Medicare Part D includes it. Some pharmacies also offer payment plans or manufacturer coupons.
If you do develop shingles, early treatment matters. Antiviral medications work best when started within 72 hours of the rash appearing, so don't wait to seek medical attention if you notice the telltale signs: pain, tingling, or burning on one side of your body, followed by a red rash and fluid-filled blisters.
The Bigger Picture
Shingles is one of those conditions that doesn't get much attention until it affects you or someone close to you. It doesn't have the dramatic urgency of a heart attack or the cultural visibility of conditions like diabetes. But its impact on quality of life can be profound and lasting.
The gap between what we know about prevention and what people are actually doing represents a real public health opportunity. When millions of people suffer from a condition we can largely prevent with two vaccine doses, something in our health communication and access isn't working.
You don't need to be "freaked out" by shingles, but you should take it seriously. This isn't about catastrophizing or health anxiety — it's about making an informed decision based on real risks and available prevention. If you're eligible for the vaccine and haven't gotten it, consider this your nudge to add it to your healthcare to-do list.
Your future self — the one who might otherwise be dealing with months of nerve pain — will likely thank you.
More in health
New research resolves a decades-old puzzle about genome architecture — with implications for understanding birth defects and cancer. ---META--- Cornell study shows disrupting 3D genome structure selectively damages developmental genes, explaining longstanding biological paradox.
Nanox's lower-cost 3D imaging system reaches rural American healthcare through regional partnership strategy
The New Jersey-based drugmaker's extended-release formulation targets a $65 million annual market dominated by brand-name Carbatrol.
Despite recent policy changes, ex-members warn that young lives remain at risk from the faith's restrictive stance on medical treatment.
Comments
Loading comments…